2.04  -0.36 (-15%)		04-19 16:00
Open: 2.32 High: 2.45 Volume: 783,234		Pre. Close: 2.4 Low: 1.97 Market Cap: 469(M)

Short term
Mid term
Targets	6-month :	3.03	1-year :	3.93
Resists	First :	2.59	Second :	3.36
Pivot price	1.82
Supports	First :	1.35	Second :	1.12
MAs	MA(5) :	2.41	MA(20) :	1.75
	MA(100) :	1.6	MA(250) :	5.42
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	51.9	D(3) :	67.8
RSI	RSI(14): 55.7
52-week	High :	13.51	Low :	1.12

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PROK ] has closed below upper band by 38.5%. Bollinger Bands are 219% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.45 - 2.47	2.47 - 2.48
Low:	1.94 - 1.96	1.96 - 1.97
Close:	2.02 - 2.04	2.04 - 2.06

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Fri, 19 Apr 2024
ProKidney (NASDAQ:PROK) Shares Down 2.5% - MarketBeat

Wed, 17 Apr 2024
ProKidney Corp. (NASDAQ:PROK) SVP Sells $145,498.19 in Stock - MarketBeat

Thu, 21 Mar 2024
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights - GlobeNewswire

Thu, 07 Mar 2024
Morgan Stanley starts ProKidney stock coverage, focus on new therapy 'REACT' - Investing.com

Mon, 12 Feb 2024
PROK Stock Quote Price and Forecast - CNN

Mon, 12 Feb 2024
ProKidney Approves New Equity Incentives to Retain Key Staff - TipRanks.com - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	62 (M)
Shares Float	43 (M)
Held by Insiders	23.1 (%)
Held by Institutions	60.7 (%)
Shares Short	13,980 (K)
Shares Short P.Month	14,300 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-18.44
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-20.2 %
Return on Equity (ttm)	-30.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-90 (M)
Levered Free Cash Flow	-77 (M)

PE Ratio	-3.58
PEG Ratio	0
Price to Book value	-0.12
Price to Sales	0
Price to Cash Flow	-1.4

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.